Wide Ranks

DNTH

Dianthus Therapeutics, Inc.

23.83

Top Statistics
Market Cap 705 M Forward PE -7.31 Revenue Growth 135.10 %
Current Ratio 18.30 Trailing PE 3.30 Earnings Growth 0.00 %
Profit Margins 0.00 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA -5.13 Enterprise / Revenue 79.11 Price To Sales Trailing12 Months 131.44
Profitability
Profit Margins 0.00 % Operating Margins -1376.61 %
Balance Sheet
Total Cash 281 M Total Cash Per Share 9.50 Total Debt 311000
Total Debt To Equity 0.0920 Current Ratio 18.30 Book Value Per Share 11.51
All Measures
Short Ratio 1962.00 % Message Board Id finmb_631649032 Shares Short Prior Month 4 M
Return On Equity -0.2599 City New York Uuid 1c256785-fa9a-34f5-a846-6abff7f6272e
Previous Close 23.86 First Trade Date Epoch Utc 1 B Book Value 11.51
Total Debt 311000 Volume 182943 Price To Book 2.07
Fifty Two Week Low 6.58 Total Cash Per Share 9.50 Total Revenue 5 M
Shares Short Previous Month Date 1 B Target Median Price 51.00 Audit Risk 6
Max Age 86400 Sand P52 Week Change 0.3133 Operating Margins -1376.61 %
Target Mean Price 51.80 Net Income To Common -67092000 Short Percent Of Float 0.2580
Implied Shares Outstanding 29 M Trailing Peg Ratio None Last Fiscal Year End 1 B
Average Daily Volume10 Day 440830 Average Volume10days 440830 Total Cash 281 M
Next Fiscal Year End 1 B Revenue Per Share 0.1900 Held Percent Insiders 0.0876
Trailing PE 3.30 Date Short Interest 1 B Most Recent Quarter 1 B
Share Holder Rights Risk 8 Regular Market Previous Close 23.86 Target Low Price 36.00
Gmt Off Set Milliseconds -18000000 Fifty Day Average 26.82 Open 23.81
Free Cashflow -43810000 State NY Dividend Yield 0.00 %
Return On Assets -0.1895 Time Zone Short Name EST Board Risk 7
Trailing Eps 7.22 Day Low 23.07 Address1 7 Times Square
Shares Outstanding 29 M Compensation Risk 8 Price Hint 2
Target High Price 84.00 Website https://dianthustx.com 52 Week Change 1.13
Average Volume 248064 Forward Eps -3.26 Recommendation Key none
Compensation As Of Epoch Date 1 B Quick Ratio 1806.50 % Is_sp_500 False
Regular Market Day High 23.99 Profit Margins 0.00 % Debt To Equity 0.0920
Fifty Two Week High 33.77 Day High 23.99 Shares Short 5 M
Regular Market Open 23.81 Industry Key biotechnology Earnings Growth 0.00 %
Enterprise To Revenue 79.11 Revenue Growth 135.10 % Shares Percent Shares Out 0.1839
Operating Cashflow -62590000 Currency USD Time Zone Full Name America/New_York
Market Cap 705 M Is_nasdaq_100 False Zip 10036
Quote Type EQUITY Industry Biotechnology Long Name Dianthus Therapeutics, Inc.
Overall Risk 8 Regular Market Day Low 23.07 Held Percent Institutions 1.12
Current Price 23.83 Address2 43rd Floor Enterprise To Ebitda -5.13
Financial Currency USD Current Ratio 18.30 Gross Margins 100.00 %
Industry Disp Biotechnology Number Of Analyst Opinions 10 Country United States
Float Shares 13 M Two Hundred Day Average 26.18 Governance Epoch Date 1 B
Enterprise Value 424 M Price To Sales Trailing12 Months 131.44 Forward PE -7.31
Regular Market Volume 182943 Ebitda -82814000 Exchange NCM
Go to Yahoo Finance Go to Seeking Alpha 
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases.

It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.

Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.